Drug Profile

Quemliclustat - Arcus Biosciences

Alternative Names: AB-680; HY-125286; Quemli; Small molecule CD73 inhibitor - Arcus Biosciences

Latest Information Update: 27 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arcus Biosciences
Developer Arcus Biosciences; Gilead Sciences; UCLAs Jonsson Comprehensive Cancer Center
Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Fluorobenzenes; Phosphonic acids; Pyrazoles; Pyridines; Small molecules
Mechanism of Action 5-nucleotidase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pancreatic cancer
New Molecular Entity Yes

Phase III Adenocarcinoma
Phase II Cholangiocarcinoma; Gastrointestinal cancer; Non-small cell lung cancer
Phase I/II Colorectal cancer
Preclinical Malignant-mesothelioma
No development reported Cancer
Discontinued Prostate cancer

27 Feb 2026 Arcus Biosciences initiates a phase I trial in healthy volunteers in USA (IV, Infusion) (NCT07364214)
26 Feb 2026 Arcus Biosciences and Gilead plans the process of rapidly winding down activities related to the phase II EDGE-Gastric studies in Gastrointestinal cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in South Korea, Serbia, France, Chile, Canada, USA (IV) (NCT05329766)
28 Jan 2026 No recent reports of development identified for phase-I development in Adenocarcinoma(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com